Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 23:2021:5716159.
doi: 10.1155/2021/5716159. eCollection 2021.

Suspected Sugammadex Hypersensitivity following Repeated Administration in the Setting of Multiple Flap Takebacks in a Brief Timespan

Affiliations
Case Reports

Suspected Sugammadex Hypersensitivity following Repeated Administration in the Setting of Multiple Flap Takebacks in a Brief Timespan

Elizabeth G Zolper et al. Case Rep Anesthesiol. .

Abstract

Sugammadex hypersensitivity is an uncommon event that typically occurs at higher doses. We report a case of suspected sugammadex hypersensitivity in a patient who developed hypoxia and bronchospasm following three administrations of the standard 2 mg/kg doses of sugammadex within 26 hours due to flap takebacks. Hypersensitivity to sugammadex was not initially suspected given that the patient had previous exposures. Diagnoses of pneumothorax, hemothorax, mucus plug, and tracheal tube malposition were immediately ruled out. Furthermore, the onset of hypoxia with sudden loss of tidal volume, development of high peak airway pressures, and temporal correlation with sugammadex administration all supported bronchospasm secondary to a hypersensitivity reaction. Sugammadex is a useful agent for neuromuscular blockade reversal; however, it is critical to carefully examine all adverse reactions. This case report highlights the importance of considering hypersensitivity reactions in the setting of repeat sugammadex administrations in a limited timeframe, such as in free flap reconstruction requiring multiple takebacks to the operating room in the setting of flap compromise.

PubMed Disclaimer

Conflict of interest statement

Dr. Song receives royalties from Elsevier for Plastic Surgery 3e/4e and Biomet Microfixation for Sternalock. All other authors declare no conflicts of interest.

References

    1. Merck Sharp & Dohme Corp. Bridion (Sugammadex) [Prescribing Information] Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp; 2015.
    1. Min K. C., Bondiskey P., Schulz V., et al. Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial. British Journal of Anaesthesia. 2018;121(4):749–757. doi: 10.1016/j.bja.2018.05.056. - DOI - PubMed
    1. de Kam P.-J., Nolte H., Good S., et al. Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. British Journal of Anaesthesia. 2018;121(4):758–767. doi: 10.1016/j.bja.2018.05.057. - DOI - PubMed
    1. Asahi Y., Omichi S., Adachi S., Kagamiuchi H., Kotani J. Hypersensitivity reaction probably induced by sugammadex. Acta Anaesthesiologica Taiwanica. 2012;50(4):183–184. doi: 10.1016/j.aat.2012.08.010. - DOI - PubMed
    1. Godai K., Hasegawa-Moriyama M., Kuniyoshi T., et al. Three cases of suspected sugammadex-induced hypersensitivity reactions. British Journal of Anaesthesia. 2012;109(2):216–218. doi: 10.1093/bja/aes137. - DOI - PubMed

Publication types

LinkOut - more resources